Skip to main content

Day: November 7, 2025

Greenstone Provides Update on Holdings of Highland Copper Company Inc.

GUERNSEY, Channel Islands, Nov. 07, 2025 (GLOBE NEWSWIRE) — Greenstone Resources II L.P. (“Greenstone”) announces that it has disposed of 117,335,620 common shares (“Shares”) in the capital of Highland Copper Company Inc. (“Highland”) at a price of $0.125 per Share for aggregate gross proceeds of $14,666,952.50 through a block trade over the facilities of an exchange in Canada (the “Transaction”). Immediately prior to the completion of the Transaction, Greenstone beneficially owned and controlled 117,335,620 Shares, representing 15.93% of the issued and outstanding Shares of Highland on a non-diluted basis. Greenstone had no dilutive securities. Immediately following completion of the Transaction, Greenstone no longer beneficially owns and controls any Shares, representing a decrease of 15.93% in Greenstone’s holdings of the Shares. This...

Continue reading

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting children Impetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric offices Private convertible notes financing will support the acquisition and re-launch of Xepi, accelerate the commercialization of ZELSUVMI for molluscum contagiosum, and for general working capital purposesDURHAM, N.C., Nov. 07, 2025 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic...

Continue reading

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&GreenCNS (Vafidemstat)Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmit Reinforcing company’s clinical, strategy and regulatory teams Expansion of ongoing Phase IIb in schizophrenia into other EU countries continues Preparations continue for new Phase II trial in aggression in Autism Spectrum DisorderOncology – Hematology (Iadademstat)Positive data in 1L AML to be presented at ASH with 100% ORR (88% CR) Positive data in R/R FLT3+ AML to be presented at ASH. RP2D selected Initiated enrollment in new Phase II trial in myeloproliferative neoplasms Enrollment in Phase I in MDS continues actively Initiated...

Continue reading

IPDN Welcomes His Highness Shaikh Ali Sultan Al Nuaimi of the UAE Royal Family as Independent Director

CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (Nasdaq: IPDN) (“IPDN” or the “Company”), a technology holding company focused on the application of AI technologies and AI-powered solutions, today announced the appointment of His Highness Shaikh Ali Sultan Al Nuaimi, a distinguished member of the Ajman Royal Family of the United Arab Emirates, to its Board of Directors as an Independent Director, effective as of November 5, 2025. This appointment is intended to support IPDN’s planned strategic expansion into the Middle East and reflects its focus on global digital innovation. His Highness Shaikh Ali Sultan Al Nuaimi has an extensive background in both business and academia. He earned a Bachelor of Science in Finance from Portland State University (USA) and a master’s degree in business administration...

Continue reading

IES Holdings to Acquire Gulf Island Fabrication

Transaction expands IES’s fabrication footprint and adds services capabilities HOUSTON and THE WOODLANDS, Texas, Nov. 07, 2025 (GLOBE NEWSWIRE) — IES Holdings, Inc. (“IES”) (NASDAQ: IESC) and Gulf Island Fabrication, Inc. (“Gulf Island”) (NASDAQ: GIFI) today announced that they have entered into a definitive agreement, providing for the acquisition of Gulf Island, a leading steel fabricator and service provider to the industrial, energy and government sectors, by IES. Under the terms of the agreement, IES will pay $12.00 in cash per Gulf Island share, or an aggregate equity value of approximately $192 million. The transaction has been approved by the boards of directors of both companies and is currently expected to close in the quarter ending March 31, 2026, subject to Gulf Island shareholder approval, regulatory approvals (including...

Continue reading

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expressionPhase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficacy by CD47 expression levelsPhase 1 trial for ALX2004, a novel EGFR-targeted ADC, is currently enrolling patients in the second dose cohort and on track to deliver initial safety data in 1H 2026Cash runway expected into Q1 2027 to support key milestones, including ALX2004 initial safety data in 1H 2026, interim data for ASPEN-09-Breast Cancer in Q3 2026Appointed Board Member Barbara Klencke, M.D., as Chief Medical OfficerCompany to host webcast including perspective from Breast Cancer Expert Dr. Peter Schmid on Friday, November 7, at...

Continue reading

Legacy Housing Announces Agreement to Purchase Assets of AmeriCasa Solutions, LLC and Addition of New Senior Management

BEDFORD, Texas, Nov. 07, 2025 (GLOBE NEWSWIRE) — Legacy Housing Corporation (NASDAQ: LEGH), a leading manufacturer of community-focused manufactured homes, today announced entering into agreement to purchase the assets of AmeriCasa Solutions, LLC (“AmeriCasa Solutions”) and its proprietary sales management platform, FutureHomeX®. Legacy Housing also announced the appointment of Norman Newton, AmeriCasa’s Chief Executive Officer, as Legacy Housing’s new Chief Revenue Officer. Legacy Housing is one of the largest producers of manufactured homes in the United States, distributing homes and “tiny houses” through a network of over 100 independent retailers and 12 company-owned stores, as well as directly to manufactured housing communities. As part of a strategic shift to accelerate revenue growth, Legacy Housing is implementing a three-pronged...

Continue reading

Conduent Reports Third Quarter 2025 Financial Results

Key Q3 2025 HighlightsDebt refinance completed Revenue and Adj. Revenue(1): $767M Pre-tax Income (Loss): $(38)M Adj. EBITDA Margin(1): 5.2% New Business Signings ACV(2): $111M Net ARR Activity Metric(2) (TTM): $25MFLORHAM PARK, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) — Conduent Incorporated (Nasdaq: CNDT), a global technology driven business process solutions and services company, today announced its third quarter 2025 financial results. Cliff Skelton, Conduent President and Chief Executive Officer, stated, “Q3 represents not only a quarter where we met guidance on Adjusted Revenue and Adjusted EBITDA Margin, but also the continuation of our drive toward year-over-year revenue growth. New business signings were consistent year over year and our Public Sector businesses had a particularly strong quarter, despite the cyclical nature...

Continue reading

illumin Reports Third Quarter 2025 Financial Results

Revenue of $38.2 Million, up 5% YoYAppointed new CRO as part of transition to an outcomes-based platform approach (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM and OTCQB: ILLMF) (“illumin” or the “Company”), a leader in digital advertising technology that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 HighlightsThird quarter 2025 revenue rose 5% year-over-year to $38.2 million, driven by 103% year-over-year growth in Exchange service revenue, partially offset by a decrease in Managed service revenue. Exchange service revenue increased to $20.5 million. Self service revenue at...

Continue reading

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information:Date: Thursday, November 13, 2025 at 4:30 PM ET Participant Dial-in (US): 1-877-407-0792 Participant Dial-in (International): 1-201-689-8263 Webcast Access: Click HereA replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. About Relmada Therapeutics, Inc.Relmada...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.